Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer

PURPOSE: Intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel constitute a standard therapy for optimally debulked ovarian cancer. Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bev...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Konner, Jason A., Grabon, Diana M., Gerst, Scott R., Iasonos, Alexia, Thaler, Howard, Pezzulli, Sandra D., Sabbatini, Paul J., Bell-McGuinn, Katherine M., Tew, William P., Hensley, Martee L., Spriggs, David R., Aghajanian, Carol A.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2011
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3667619/
https://ncbi.nlm.nih.gov/pubmed/22067389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.1352
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires